Grants and Contributions:
Title:
Clinical grade genome engineering of CAR-T cells
Agreement Number:
953930
Agreement Value:
$110,220.00
Agreement Date:
Jul 13, 2020 - Aug 1, 2023
Description:
The main goal of this work is to create a made-in-Canada clinical ready approach for genome editing of CAR-T for cancer immunotherapy. The project aims to enhance the potency of single-domain antibody (sdAb) targeted CAR-Ts being developed by the Cell and Gene Therapy program, through site specific integration into rationally selected gene loci under conditions that are conducive to GMP CAR-T manufacture.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Vancouver, British Columbia, CA V5Z 1L3
Reference Number:
172-2020-2021-Q2-953930
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
863530135
Recipient Type:
Not-for-profit organization or charity
Additional Information:
This agreement has been amended 2 time. The end date of this agreements has been modified by 180 days
Amendment Date
Feb 28, 2023
Recipient's Legal Name:
BC Cancer, part of the Provincial Health Services Authority
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710
Amendments: